Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2AO6J
|
|||
| Drug Name |
BIIB094
|
|||
| Synonyms |
ION859
Click to Show/Hide
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 1 | [1] | |
| Company |
Ionis; Biogen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leucine-rich repeat kinase 2 (LRRK2) | Target Info | Inhibitor | [2] |
| Leucine-rich repeat serine/threonine-protein kinase 2 messenger RNA (LRRK2 mRNA) | Target Info | . | [2] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03976349) A Phase 1 Single- and Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB094 Administered Intrathecally to Adults With Parkinson's Disease. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Ionis | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.